1. Show article details.

    BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland

    Business Wire – 1:00 AM ET 05/17/2022

    BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland.

  2. Show article details.

    Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

    Benzinga – 11:55 AM ET 05/13/2022

    By Molly Wen. With domestic competition heating up in the crowded China pharma market, innovative drug makers have begun venturing overseas in search of new opportunities. One company learning that lesson now is Innovent Biologics Inc. , an innovator in the field of PD-1 inhibitors that are an increasingly popular category of immuno-drugs for treating cancer.

  3. Show article details.

    MSCI to reshuffle stock indexes after quarterly review

    Reuters – 5:52 PM ET 05/12/2022

    MSCI said on Thursday 88 securities will be added to and 109 more will be deleted from its widely followed MSCI ACWI Index after its semi-annual index review. The three largest additions measured by market capitalization will be California-based Roblox Corp (RBLX), Sweden's Volvo Car and Quanta Services (PWR), based in Texas. All changes will be made as of the close of May 31, MSCI said.

  4. Show article details.

    BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

    Business Wire – 10:00 AM ET 05/12/2022

    Data from four pivotal trials continue to build evidence base for BRUKINSA® in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy and in combination with zanubrutinib BeiGene (BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients wo...

  5. Show article details.

    99 Biggest Movers From Yesterday

    Benzinga – 4:29 AM ET 05/12/2022

    99 Biggest Movers From Yesterday

  6. Show article details.

    52 Stocks Moving In Wednesday's Mid-Day Session

    Benzinga – 12:25 PM ET 05/11/2022

    52 Stocks Moving In Wednesday's Mid-Day Session

  7. Show article details.

    34 Stocks Moving in Wednesday's Pre-Market Session

    Benzinga – 7:05 AM ET 05/11/2022

    Don't forget to check out our premarket coverage here .

  8. Show article details.

    Where BeiGene Stands With Analysts

    Benzinga – 10:33 AM ET 05/09/2022

    Within the last quarter, BeiGene has observed the following analyst ratings: According to 5 analyst offering 12-month price targets in the last 3 months, BeiGene has an average price target of $289.0 with a high of $338.00 and a low of $177.00. Below is a summary of how these 5 analysts rated BeiGene over the past 3 months.

  9. Show article details.

    Recap: BeiGene Q1 Earnings

    Benzinga – 9:03 AM ET 05/05/2022

      BeiGene reported its Q1 earnings results on Thursday, May 5, 2022. Here's what investors need to know about the announcement. BeiGene beat estimated earnings by 10.36%, reporting an EPS of $-4.24 versus an estimate of $-4.73. Revenue was down $299.25 million from the same period last year.

  10. Show article details.

    BeiGene Reports First Quarter 2022 Financial Results

    Business Wire – 7:00 AM ET 05/05/2022

    CAMBRIDGE, Mass. “I have never been more confident in BeiGene (BGNE). Julia Wang, Chief Financial Officer, commented, “During the first quarter we saw product revenue grow meaningfully across our commercial portfolio and geographies, led by internally developed medicines, and we expect continued momentum based on approvals secured to date and upcoming milestones.

  11. Show article details.

    BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

    Business Wire – 5:53 AM ET 05/04/2022

    BeiGene (BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration has granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory CD19-positive B-c...

  12. Show article details.

    BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

    Business Wire – 7:00 AM ET 04/29/2022

    Flagship U.S. Facility Will Include Biologic Manufacturing and Late Stage Research and Clinical Development of Innovative Cancer Medicines Sixth U.S. Location Adds to Global Expansion and Brings New Jobs to New Jersey HOPEWELL, N.J. & CAMBRIDGE, Mass.

  13. Show article details.

    BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia

    Business Wire – 7:00 AM ET 04/28/2022

    BRUKINSA is now available in four countries in Latin America, following previous approvals in Brazil, Chile, and Ecuador Under an exclusive distribution agreement, Adium will commercialize BRUKINSA in Latin America BeiGene (BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, tod...

  14. Show article details.

    BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting

    Business Wire – 10:00 AM ET 04/27/2022

    Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3 trial in Waldenström macroglobulinemia CAMBRIDGE, Mass.

  15. Show article details.

    Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

    Benzinga – 9:45 AM ET 04/27/2022

    Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

  16. Show article details.

    The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

    Benzinga – 8:45 AM ET 04/27/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. Pfizer Inc  and BioNTech SE  have submitted an FDA Emergency Use Authorization application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age.

  17. Show article details.

    Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma

    Business Wire – 6:00 AM ET 04/27/2022

    CAMBRIDGE, Mass. “ESCC is a difficult to treat disease that imposes a significant symptom burden on patients. Tislelizumab is currently under review by the U.S. Food and Drug Administration and the European Medicines Agency for advanced or metastatic ESCC after prior chemotherapy.

  18. Show article details.

    The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy

    Benzinga – 9:04 AM ET 04/26/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: Protagonist Therapeutics Inc  announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis patients.

  19. Show article details.

    BeiGene Introduces Global Environmental, Social, and Governance Strategy

    Business Wire – 7:00 AM ET 04/26/2022

    Change Is the Cure™, BeiGene’s ESG strategy and framework launched in 2021, defines the Company’s aspirational reason for thinking beyond its products and provides a path to help create a better world BeiGene (BGNE), Ltd., a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today intro...

  20. Show article details.

    Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene

    PR Newswire – 4:09 PM ET 04/25/2022

    BEIJING, April 25, 2022 Biocytogen Pharmaceuticals Co., Ltd. reached an agreement with BeiGene Co., Ltd. for licensing Biocytogen's fully human antibody RenMab™/RenLite™ mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.


Today's and Upcoming Events

  • Aug

    BGNE to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May

    BGNE announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

See the Latest Features
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.